Valuation: Lexaria Corp

Market Cap 14.94M 12.91M 12.14M 11.03M 20.72M 1.43B 21.08M 142M 55.56M 715M 56.06M 54.87M 2.38B P/E 2026 *
-2.23x
P/E 2027 * -1.94x
Enterprise Value 14.94M 12.91M 12.14M 11.03M 20.72M 1.43B 21.08M 142M 55.56M 715M 56.06M 54.87M 2.38B EV / Sales 2026 *
747x
EV / Sales 2027 * 10.6x
Free-Float
96.68%
Yield 2026 *
-
Yield 2027 * -
Manager TitleAgeSince
Chief Executive Officer 57 2024-08-30
Director of Finance/CFO 66 2024-09-30
President 55 2015-04-14
Director TitleAgeSince
Chairman 65 2006-10-25
Director/Board Member 72 2011-07-07
Director/Board Member 55 2016-04-28
Change 5-day change 1-year change 3-year change Capi.($)
-2.25%-0.47%+68.30%+116.05% 1,052B
-0.66%+0.43%+47.39%+51.02% 627B
-0.54%+1.39%+20.69%+64.61% 441B
-1.99%-3.32%+38.71%+36.26% 349B
-1.05%-2.81%+23.07%+35.91% 287B
-2.12%-3.67%-1.14%+5.37% 241B
-0.63%+1.04%+40.05%+56.67% 224B
-1.19%-3.41%-9.57%-53.50% 202B
+0.16%+3.87%+16.89%+77.38% 172B
Average -1.14%+0.43%+27.15%+43.31% 399.46B
Weighted average by Cap. -1.36%+0.32%+39.09%+61.76%

Financials

2026 *2027 *
Net sales 20K 17.28K 16.25K 14.77K 27.74K 1.91M 28.22K 190K 74.39K 957K 75.06K 73.46K 3.18M 1.4M 1.21M 1.14M 1.04M 1.95M 134M 1.98M 13.35M 5.22M 67.14M 5.27M 5.15M 223M
Net income -6.64M -5.74M -5.4M -4.9M -9.21M -633M -9.37M -63.18M -24.69M -318M -24.92M -24.38M -1.06B -8.95M -7.73M -7.27M -6.61M -12.41M -854M -12.62M -85.15M -33.28M -428M -33.58M -32.86M -1.42B
Net Debt - -
Logo Lexaria Corp
Lexaria Bioscience Corp. is a Canada-based biotechnology company. The Company's patented drug delivery formulation and processing platform technology improves the way a wide variety of drugs enter the bloodstream, always through oral delivery. DehydraTECH has also evidenced an ability to deliver some drugs effectively across the blood brain barrier. The Company’s segment includes Intellectual Property, B2B Production, and Research and Development. It is advancing several research and development (R&D) activities in both preclinical and clinical programs. Its focus is the investigation and the incorporation of its DehydraTECH drug delivery technology with glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) to enhance absorption and reduce adverse side effects. The Company operates a licensed in-house research laboratory and holds an intellectual property portfolio with around 48 patents granted and many patents pending worldwide.
Employees
-
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-